You are here: Industry Insights > CALAVI

News List

Calquence fails to prevent respiratory failure in COVID-19 patients europeanpharmaceuticalreview
November 16, 2020
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients worldpharmanews
June 08, 2020
Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease.(1)
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 worldpharmanews
April 15, 2020
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.